Autoimmune polyendocrine syndrome screening

Autoimmune polyendocrine syndrome Microchapters
Home
Patient Information
Overview
Historical Perspective
Classification
Pathophysiology
Causes
Differentiating Autoimmune polyendocrine syndrome from other Diseases
Epidemiology and Demographics
Risk Factors
Screening
Natural History, Complications and Prognosis
Diagnosis
Diagnostic study of choice
History and Symptoms
Physical Examination
Laboratory Findings
Electrocardiogram
X Ray
CT
MRI
Echocardiography or Ultrasound
Other Imaging Findings
Other Diagnostic Studies
Treatment
Medical Therapy
Surgery
Primary Prevention
Secondary Prevention
Cost-Effectiveness of Therapy
Future or Investigational Therapies
Case Studies
Case #1
Autoimmune polyendocrine syndrome screening On the Web
Most recent articles
Most cited articles
Review articles
CME Programs
Powerpoint slides
Images
American Roentgen Ray Society Images of Autoimmune polyendocrine syndrome screening All Images X-rays Echo & Ultrasound CT Images MRI
Ongoing Trials at Clinical Trials.gov
US National Guidelines Clearinghouse
NICE Guidance
FDA on Autoimmune polyendocrine syndrome screening
CDC on Autoimmune polyendocrine syndrome screening
Autoimmune polyendocrine syndrome screening in the news
Blogs on Autoimmune polyendocrine syndrome screening
Directions to Hospitals Treating Autoimmune polyendocrine syndrome
Risk calculators and risk factors for Autoimmune polyendocrine syndrome screening

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief:

Overview

There is insufficient evidence to recommend routine screening for [disease/malignancy].

OR

According to the [guideline name], screening for [disease name] is not recommended.

OR

According to the [guideline name], screening for [disease name] by [test 1] is recommended every [duration] among patients with [condition 1], [condition 2], and [condition 3].

Screening

Screening is an important aspect in early diagnosis and management of autoimmune polyendocrine syndrome (APS). In patients of APS, high clinical suspicion should be maintained for presence of other autoimmune disorders.

• In APS type 1 the time interval between onset of mucocutaneous candidiasis and hypoparathyroidism may take upto five years and further involvement of adrenal glands may take upto ten years. Thus, a high degree of clinical suspicion is necessary in patients with a single autoimmune endocrine disorder.
• Once a patient has been diagnosed with a single autoimmune disorder. screening should be done for presence of other auto-antibodies such as 21- hydroxylase, 17-hydroxylase, thyroid peroxidase, parietal cell, anti-intrinsic factor and islet cell antibodies.

• There is insufficient evidence to recommend routine screening for [disease/malignancy].

OR

• According to the [guideline name], screening for [disease name] is not recommended.

OR

• According to the [guideline name], screening for [disease name] by [test 1] is recommended every [duration] among patients with:
  • [condition 1]
  • [condition 2]
  • [condition 3]